TNXP Quote, Financials, Valuation and Earnings

Citius Oncology, Inc. has a net margin of -972.95% compared to Tonix Pharmaceuticals Holding Corp.'s net margin of --. Tonix Pharmaceuticals Holding Corp.'s return on equity of -62.54% beat Citius Oncology, Inc.'s return on equity of -64.23%.

Tonix Pharmaceuticals Holding Corp. has a consensus price target of $66.33, signalling upside risk potential of 328.51%. On the other hand Citius Oncology, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 450.46%. Given that Citius Oncology, Inc. has higher upside potential than Tonix Pharmaceuticals Holding Corp., analysts believe Citius Oncology, Inc. is more attractive than Tonix Pharmaceuticals Holding Corp..

Tonix Pharmaceuticals Holding Corp. has a beta of 1.781, which suggesting that the stock is 78.138% more volatile than S&P 500. In comparison Citius Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Tonix Pharmaceuticals Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding Corp. pays -- of its earnings as a dividend. Citius Oncology, Inc. pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding Corp. quarterly revenues are $3.3M, which are larger than Citius Oncology, Inc. quarterly revenues of --. Tonix Pharmaceuticals Holding Corp.'s net income of -$32M is lower than Citius Oncology, Inc.'s net income of -$5M. Notably, Tonix Pharmaceuticals Holding Corp.'s price-to-earnings ratio is -- while Citius Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding Corp. is 8.34x versus -- for Citius Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of -972.95% compared to Tonix Pharmaceuticals Holding Corp.'s net margin of 10.24%. Tonix Pharmaceuticals Holding Corp.'s return on equity of -62.54% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Tonix Pharmaceuticals Holding Corp. has a consensus price target of $66.33, signalling upside risk potential of 328.51%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.88%. Given that Tonix Pharmaceuticals Holding Corp. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Tonix Pharmaceuticals Holding Corp. is more attractive than Amicus Therapeutics, Inc..

Tonix Pharmaceuticals Holding Corp. has a beta of 1.781, which suggesting that the stock is 78.138% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.

Tonix Pharmaceuticals Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding Corp. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding Corp. quarterly revenues are $3.3M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Tonix Pharmaceuticals Holding Corp.'s net income of -$32M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Tonix Pharmaceuticals Holding Corp.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding Corp. is 8.34x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -972.95% compared to Tonix Pharmaceuticals Holding Corp.'s net margin of -255.85%. Tonix Pharmaceuticals Holding Corp.'s return on equity of -62.54% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Tonix Pharmaceuticals Holding Corp. has a consensus price target of $66.33, signalling upside risk potential of 328.51%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -95.56%. Given that Tonix Pharmaceuticals Holding Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Tonix Pharmaceuticals Holding Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

Tonix Pharmaceuticals Holding Corp. has a beta of 1.781, which suggesting that the stock is 78.138% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Tonix Pharmaceuticals Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Tonix Pharmaceuticals Holding Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding Corp. quarterly revenues are $3.3M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Tonix Pharmaceuticals Holding Corp.'s net income of -$32M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Tonix Pharmaceuticals Holding Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 32.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding Corp. is 8.34x versus 37.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Soligenix, Inc. has a net margin of -972.95% compared to Tonix Pharmaceuticals Holding Corp.'s net margin of -1636.63%. Tonix Pharmaceuticals Holding Corp.'s return on equity of -62.54% beat Soligenix, Inc.'s return on equity of -248.07%.

Tonix Pharmaceuticals Holding Corp. has a consensus price target of $66.33, signalling upside risk potential of 328.51%. On the other hand Soligenix, Inc. has an analysts' consensus of $17.50 which suggests that it could grow by 1196.3%. Given that Soligenix, Inc. has higher upside potential than Tonix Pharmaceuticals Holding Corp., analysts believe Soligenix, Inc. is more attractive than Tonix Pharmaceuticals Holding Corp..

Tonix Pharmaceuticals Holding Corp. has a beta of 1.781, which suggesting that the stock is 78.138% more volatile than S&P 500. In comparison Soligenix, Inc. has a beta of 1.946, suggesting its more volatile than the S&P 500 by 94.604%.

Tonix Pharmaceuticals Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soligenix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding Corp. pays -- of its earnings as a dividend. Soligenix, Inc. pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding Corp. quarterly revenues are $3.3M, which are larger than Soligenix, Inc. quarterly revenues of --. Tonix Pharmaceuticals Holding Corp.'s net income of -$32M is lower than Soligenix, Inc.'s net income of -$2.5M. Notably, Tonix Pharmaceuticals Holding Corp.'s price-to-earnings ratio is -- while Soligenix, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding Corp. is 8.34x versus -- for Soligenix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.